coramitug

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

Participants with transthyretin amyloid cardiomyopathy (ATTR CM)The present study will include a population of patients with established ATTR CM.Transthyretin Amyloid Cardiomyopathy

Phase 1

A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.

Not yet recruitingNCT07448623

Novo Nordisk A/STransthyretin Amyloid Cardiomyopathy

Start: 2026-03-02End: 2028-07-25Target: 14Updated: 2026-03-04

Phase 2

Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).

CompletedCTIS2023-506824-96-00

Novo Nordisk A/SThe present study will include a population of patients with established ATTR CM.

Start: 2023-05-23End: 2025-04-30Target: 61Updated: 2025-04-11

Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (ATTR CM)

Active, not recruitingCTIS2022-502605-15-00

Novo Nordisk A/SParticipants with transthyretin amyloid cardiomyopathy (ATTR CM)

Start: 2024-09-16Target: 58Updated: 2025-11-24